ArticlePloS one2013
Conflicts of interest among authors of clinical practice guidelines for glycemic control in type 2 diabetes mellitus.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review.BMJ (Clinical research ed.) · 2020Pooled it
- Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations.The Cochrane database of systematic reviews · 2020Pooled it
- Diversity representation in the development of respiratory society guidance documents.ERJ open research · 2026Article
- The sugar industry's efforts to manipulate research on fluoride effectiveness and toxicity: a ninety-year history.Environmental health : a global access science source · 2025Article
- A cross-sectional review of policies on conflicts of interest and funding in the development manuals of practice guidelines.Clinical and public health guidelines · 2025Article
- Article
- Intellectual conflicts of interest among cardiology and pulmonology clinical practice guidelines.PloS one · 2023Article
- Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs.Journal of bioethical inquiry · 2021Review
- Financial Conflicts of Interest in Clinical Practice Guidelines: A Systematic Review.Mayo Clinic proceedings. Innovations, quality & outcomes · 2021Review
- A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.PloS one · 2021Article
- Analysis of conflict of interest policies among organizations producing clinical practice guidelines.PloS one · 2021Article
- Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study.BMJ (Clinical research ed.) · 2017Observational
- Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase.BMC health services research · 2016Article
- Policies on Conflicts of Interest in Health Care Guideline Development: A Cross-Sectional Analysis.PloS one · 2016Article
- Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors.Croatian medical journal · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundConflict of interest (COI) is an important potential source of bias in the development of clinical practice guidelines (CPGs).
objectivesTo examine rates of disclosure of COI, including financial interests in companies that manufacture drugs that are recommended in CPGs on glycemic control in type 2 diabetes mellitus, and to explore the relationship between recommendations for specific drugs in a guideline and author COI.
methodsWe identified a cohort of relevant guidelines from the National Guideline Clearinghouse (NGC) and abstracted COI disclosures from all guideline authors for this observational, cross-sectional study. We determined which hypoglycemic drugs were recommended in each guideline, and explored the relationship between specific disclosures and whether a drug was recommended.
resultsAmong 13 included guidelines, the percentage of authors with one or more financial disclosures varied from 0 to 94% (mean 44.2%), and was particularly high for two US-based guidelines (91% and 94%). Three guidelines disclosed no author financial COI. The percentage of authors with disclosures of financial interests in manufacturers of recommended drugs was also high (mean 30%). On average, 56% of manufacturers of patented drugs recommended in each guideline had one or more authors with a financial interest in their company. We did not find a significant relationship between financial interests and whether a drug was recommended in our sample; US-based guidelines were more likely to make recommendations for a specific drug compared to non-US based guidelines. DISCUSSION: Authors of this cohort of guidelines have financial interests directly related to the drugs that they are recommending. Although we did not find an association between author COI and drugs recommended in these guidelines and we cannot draw conclusions about the validity of the recommendations, the credibility of many of these guidelines is in doubt.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.